Physician profile
Mohammad A Ansari
NPI 1164520581
$3,988.19
in general payments reported to CMS, 2019-2025
24 companies · $1,386 in 2025
The $1,386 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $279 · 2021: $295 · 2022: $411 · 2023: $633 · 2024: $420 · 2025: $1,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,025 · Education: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,024.57 |
| Education | $414.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,115.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $359.35 | 2019-2025 | Breztri |
| Regeneron Healthcare Solutions, INC. | $302.91 | 2024-2025 | Dupixent |
| Insmed, INC. | $297.65 | 2024-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $275.48 | 2019-2025 | |
| Amgen INC. | $245.99 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.09 | 2019-2025 | Jascayd, Ofev |
| Electromed, INC. | $153.41 | 2022-2023 | Smartvest |
| Abiomed | $148.32 | 2025 | |
| Pfizer INC. | $147.02 | 2022-2025 | |
| Advanced Respiratory, INC | $119.35 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $101.19 | 2021 | |
| Grifols USA, LLC | $94.86 | 2022-2024 | Prolastin-C Liquid |
| Lilly USA, LLC | $76.97 | 2025 | Zepbound |
| Viatris Specialty LLC | $66.99 | 2025 | Yupelri |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Datascope Corp. | $66.33 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $53.96 | 2025 | Gemtesa |
| Mylan Specialty L.P. | $46.11 | 2020 | |
| Baxter Healthcare | $23.45 | 2022 | |
| Philips North America LLC | $19.33 | 2024 | (Ak6) Vest Therapy |
| Pulmonx Corporation | $16.39 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Sunovion Pharmaceuticals INC. | $16.05 | 2019 | |
| Exact Sciences Corporation | $15.25 | 2025 | Cologuard Collection Kit |
| La Jolla Pharmaceutical Company | $14.97 | 2023 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.